These 10 small to midsize businesses have seen returns ranging from 210 to 670% in just nine months. See which sector makes up most of this high-flying crowd. More
-
-
Sponsored By:
-
Sponsored By:
ARNA
Europe May Reject Vivus’ Obesity Drug, Shares Drop
Vivus said that, based on feedback it has received, European regulators will likely reject its new obesity drug Qsiva, which is already approved in the U.S. More
8 Biotechnology Stocks to Buy Now
This week, 8 Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an "A" ("strong buy") or "B" overall ("buy"). More
Stocks Barely on Track: Tuesday’s IP Market Recap
Stocks started on the way up in the morning on good foreign and domestic news, but gave up some in the afternoon. The Dow barely finished up for the day. More
Arena Narrows Loss, Grows Revenue
Arena Pharmaceuticals saw less of a loss in the second quarter thanks to a payment related to its newly-approved obesity drug. More
Travel Stocks Put on Hold — Wednesday’s IP Market Recap
The Dow Jones and S&P 500 both managed to extend their gains streaks to four consecutive days, but Priceline, Orbitz and the rest of the travel sector didn't join in. More
Is Arena Pharmaceuticals Any More Attractive Now That the Dust Is Settling?
Now that the Belviq approval-fueled craze has waned, investors can take a clearer look at Arena's numbers. They might be pleasantly surprised. More
